Orlagh Feeney

Orlagh Feeney is a Research Fellow and Nanomedicine team lead in the Porter Group at Monash Institute of Pharmaceutical Sciences (MIPS), Monash University. She specializes in advanced drug delivery systems with a focus on cancer and autoimmune diseases, emphasizing translational research derived from her six-year pharmaceutical R&D experience in Ireland.

Her research interests include controlling pharmacokinetics, lymphatic exposure, and targeted drug delivery strategies such as active targeting and stromal modification. She leads projects like the 'Role of Hyaluronan in Antigen and Immune Cell Trafficking' and developed disease models for solid cancers and collagen-induced arthritis.

Key contributions include studies on polymer nanorod-drug conjugates, intestinal lymphatic drug delivery, and lymphatic targeting of immunotherapies. She co-edited a Molecular Pharmaceutics special issue on Australasian innovations and serves as a peer reviewer.

Feeney's work aligns with UN SDGs addressing good health and well-being, leveraging lymphatic pathways to enhance therapeutic efficacy in oncology and autoimmune therapies.